From July 1, 2021 to September 30, 2021, the company has repurchased 2,886,900 shares, representing 0.52% for CNY 29.81 million. With this, the company has completed the repurchase of 19,086,325 shares, representing 3.39% for CNY 184.47 million under the buyback announced on February 2, 2021.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
25.86 CNY | +0.62% | -3.33% | +51.14% |
05-13 | Lingrui Pharma Gets Green Light to Market Type 2 Diabetes Drug | MT |
04-25 | Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+51.14% | 2.02B | |
+44.36% | 6.34B | |
-13.52% | 4.61B | |
+10.85% | 3.39B | |
-6.52% | 3.29B | |
-5.22% | 1.73B | |
+1.29% | 1.67B | |
+57.69% | 1.63B | |
-9.67% | 1.59B | |
+37.14% | 1.34B |
- Stock Market
- Equities
- 600285 Stock
- News Henan Lingrui Pharmaceutical Co., Ltd.
- Tranche Update on Henan Lingrui Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on February 2, 2021.